Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

被引：48
|
作者：
Sharma, Padmanee
Pachynski, Russell Kent
Narayan, Vivek
Flechon, Aude
Gravis, Gwenaelle
Galsky, Matt D.
Mahammedi, Hakim
Patnaik, Akash
Subudhi, Sumit Kumar
Ciprotti, Marika
Duan, Tao
Saci, Abdel
Hu, Sarah
Han, G. Celine
Fizazi, Karim
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[4] Ctr Leon Berard, Lyon, France
[5] Inst Paoli Calmettes, Med Oncol, Marseille, France
[6] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[7] Ctr Jean Perrin, Clermont Ferrand, France
[8] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
[9] Bristol Myers Squibb, Princeton, NJ USA
[10] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
142
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase III Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC): A randomized, double-blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with metastatic castration-resistant Prostate Cancer (CheckMate-7DX) - AUO Study AP 118/21
    Rexer, Heidrun
    Boegemann, Martin
    Hammerer, Peter
    AKTUELLE UROLOGIE, 2022, 53 (03) : 226 - 228
  • [32] Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC)
    Siegel, Adam Phillip
    Bryce, Alan Haruo
    Lin, Amy M.
    Friedlander, Terence W.
    Hsieh, Andrew Caleb
    Hang, Evelyn
    Weinberg, Vivian K.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)
    Chen, Yu-Wei
    Liu, Lin
    Pu, Minya
    Pena, Samuel
    Qin, Qian
    Zhang, Tian
    Emamekhoo, Hamid
    Lang, Joshua Michael
    Patnaik, Akash
    McKkay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS239 - TPS239
  • [34] Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
    Mark C. Markowski
    Mary-Ellen Taplin
    Rahul Aggarwal
    Laura A. Sena
    Hao Wang
    Hanfei Qi
    Aliya Lalji
    Victoria Sinibaldi
    Michael A. Carducci
    Channing J. Paller
    Catherine H. Marshall
    Mario A. Eisenberger
    David E. Sanin
    Srinivasan Yegnasubramanian
    Carolina Gomes-Alexandre
    Busra Ozbek
    Tracy Jones
    Angelo M. De Marzo
    Samuel R. Denmeade
    Emmanuel S. Antonarakis
    Nature Communications, 15
  • [35] Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
    Markowski, Mark C.
    Taplin, Mary-Ellen
    Aggarwal, Rahul
    Sena, Laura A.
    Wang, Hao
    Qi, Hanfei
    Lalji, Aliya
    Sinibaldi, Victoria
    Carducci, Michael A.
    Paller, Channing J.
    Marshall, Catherine H.
    Eisenberger, Mario A.
    Sanin, David E.
    Yegnasubramanian, Srinivasan
    Gomes-Alexandre, Carolina
    Ozbek, Busra
    Jones, Tracy
    De Marzo, Angelo M.
    Denmeade, Samuel R.
    Antonarakis, Emmanuel S.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [36] Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Mohebtash, M.
    Madan, R. A.
    Arlen, P. M.
    Rauckhorst, M.
    Tsang, K. Y.
    Cereda, V.
    Vergati, M.
    Poole, D. J.
    Dahut, W. L.
    Schlom, J.
    Gulley, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Phase I clinical study of cabazitaxel plus prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in a Japanese population.
    Takahashi, Shunji
    Mukai, Hirofumi
    Uemura, Hirotsugu
    Uemura, Hiroji
    Kosaka, Takeo
    Nishiyama, Hiroyuki
    Suzuki, Kazuhiro
    Kakehi, Yoshiyuki
    Okihara, Koji
    Namiki, Shunichi
    Ogawa, Osamu
    Kato, Masashi
    Nakai, Yasutomo
    Ohno, Keiji
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [38] Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Gulley, James L.
    Madan, Ravi A.
    Tsang, Kwong Y.
    Jochems, Caroline
    Dahut, William L.
    Schlom, Jeffrey
    CANCER RESEARCH, 2013, 73
  • [39] Phase-III Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) A randomized, double-blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with metastatic castration-resistant Prostate Cancer (CheckMate-7DX) - Study AP 118/21 of the AUO
    Rexer, H.
    Boegemann, M.
    Hammerer, P.
    UROLOGE, 2022, 61 (03): : 345 - 346
  • [40] Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Gamat-Huber, Melissa
    Jeon, Donghwan
    Johnson, Laura E.
    Moseman, Jena E.
    Muralidhar, Anusha
    Potluri, Hemanth K.
    Rastogi, Ichwaku
    Wargowski, Ellen
    Zahm, Christopher D.
    McNeel, Douglas G.
    CANCERS, 2020, 12 (10) : 1 - 23
12345